Wednesday, November 12, 2025

Continuity at the Top: Dr. Hans-Peter Hubmann remains Chairman of the German Institute for Drug Testing (DAPI)

The members of the German Institute for Drug Testing (DAPI) have elected a new board, opting for continuity and experience: Dr. Hans-Peter Hubmann (61) was unanimously re-elected as Chairman. He has led the institute since 2021 and will continue to do so for another four-year term.

“We contribute through our publications and expert reports to the improvement of drug therapy safety. In addition, our analyses support pharmacists’ chambers and associations in preparing negotiations, training sessions, and events. I am very pleased to continue leading DAPI in the coming years,” said Hubmann after his re-election.

Cathrin Burs (62), President of the Chamber of Pharmacists of Lower Saxony, remains Deputy Chairwoman, also elected unanimously.

The newly elected board members are:

• Thomas Benkert (69), Honorary President of the Federal Chamber of Pharmacists
• Dr. Peter Froese (65), Chairman of the Supervisory Board of GEDISA mbH
• Prof. Dr. Martin Schulz (66), Managing Director for Pharmaceuticals at ABDA and Chairman of the Drug Commission of German Pharmacists (AMK)

Prof. Dr. Schulz joins the board as a new member, having previously served as one of DAPI’s two Managing Directors. Dr. Sebastian Schmitz (66), Chief Executive Officer of ABDA, did not stand for re-election and has left the board.

The DAPI is a non-profit association supported by 15 regional chambers of pharmacists and 15 regional pharmacists’ associations. Around 250 individual members also contribute to its work through their annual membership fees. DAPI provides valuable data analyses and expert reports that make a significant contribution to the advancement of pharmaceutical care and public health in Germany.